Results 111 to 120 of about 107,749 (252)

A Targeted Quantitative Proteomic Method Revealed a Substantial Reprogramming of Kinome during Melanoma Metastasis. [PDF]

open access: yes, 2020
Kinases are involved in numerous critical cell signaling processes, and dysregulation in kinase signaling is implicated in many types of human cancers.
Guo, Lei   +6 more
core   +1 more source

Gastrointestinal strictures in a pediatric patient with Satoyoshi syndrome

open access: yesJPGN Reports, EarlyView.
Abstract We present a novel case of gastrointestinal strictures in a young girl with Satoyoshi syndrome (SS), highlighting multi‐system features of alopecia universalis, painful muscle cramps with dystonia, aberrant growth velocity, and skeletal abnormalities.
Katherine (Tusia) Pohoreski   +5 more
wiley   +1 more source

Efficacy of upadacitinib induction for pediatric inflammatory bowel disease

open access: yesJPGN Reports, EarlyView.
Abstract Objectives Upadacitinib, a second‐generation Janus kinase (JAK) inhibitor, is approved for moderate to severe Crohn's disease (CD) and ulcerative colitis (UC) in adults. Its efficacy in pediatric patients remains unclear, though early reports suggest benefits in refractory inflammatory bowel disease (IBD).
Evan Greenhall   +5 more
wiley   +1 more source

Combined therapy with IL-1 and JAK inhibitors in a patient with the NLRP1 gene mutation and a complex inflammatory phenotype

open access: yesJournal of Allergy and Clinical Immunology: Global
A patient presented with overlapping clinical and laboratory features of 2 rare autoinflammatory diseases, NLRP1-associated autoinflammation with arthritis and dyskeratosis and familial multiple self-healing palmoplantar carcinoma.
Vasily Burlakov, MD   +7 more
doaj   +1 more source

Successful treatment of eosinophilic esophagitis with upadacitinib prescribed for atopic dermatitis

open access: yesJPGN Reports, EarlyView.
Abstract We describe a pediatric patient treated with upadacitinib for atopic dermatitis (AD) who subsequently achieved sustained clinical and histologic remission of eosinophilic esophagitis (EoE). Upadacitinib is an oral small molecule selective Janus kinase 1 inhibitor that inhibits janus kinase‐signal transduction and activation of transcription ...
Nathalie Nguyen, Maureen Bauer
wiley   +1 more source

Turmeric and curcumin: From traditional medicine to modern therapeutic applications

open access: yesJSFA reports, EarlyView.
Abstract Turmeric (Curcuma longa), a medicinal plant, has maintained its cultural and therapeutic significance over centuries in Ayurveda, Unani, and Traditional Chinese Medicine. However, novel formulations and delivery methods are being developed to address these challenges.
Azma Nadeem   +7 more
wiley   +1 more source

Frontiers in Pigment Cell and Melanoma Research

open access: yes, 2018
We identify emerging frontiers in clinical and basic research of melanocyte biology and its associated biomedical disciplines. We describe challenges and opportunities in clinical and basic research of normal and diseased melanocytes that impact current ...
Birlea, Stanca   +26 more
core   +1 more source

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson   +4 more
wiley   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender   +2 more
wiley   +1 more source

Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis

open access: yesJournal of Experimental Pharmacology, 2018
Suliman Al-Fayoumi,1 Taishi Hashiguchi,2 Yuka Shirakata,2 John Mascarenhas,3 Jack W Singer1 1CTI BioPharma, Seattle, WA, USA; 2SMC Laboratories, Tokyo, Japan; 3Tish Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Background ...
Al-Fayoumi S   +4 more
doaj  

Home - About - Disclaimer - Privacy